ESMO Sept 28th 2014 in Madrid: Presentation of the COU-AA-302 study

Charles Ryan, M.D., Professor of Clinical Medicine, Urology at the University of California, San Francisco, and lead investigator of the COU-AA-302 study, will on Sunday September 28^th 11.00 – 12.30 present the following abstract at ESMO:

Final overall survival (OS) analysis of COU-AA-302, a randomized phase 3 study of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) without prior chemotherapy.

Find the abstract here:

For media enquiries and interviews with Charles Ryan please contact:
Satu Glawe, +49 172 294 6264, sglawe@its.jnj.com
Johan Dahlin, +46 72 553 9230, jdahlin@its.jnj.com